Long-term

Cholesterol Changes in Menopause

Creator: Dr Nadira Awal
Published: 2026-01-15

Why LDL often rises after menopause and what actually helps.

By Dr Nadira AwalBMS Specialist4 min readMedically reviewed 9 July 2026

Almonds, oily fish and olive oil on a stone board with linen

Falling oestrogen shifts your lipid profile. Diet, movement, weight and (where appropriate) statins are all part of the modern midlife toolkit.

Cholesterol behaviour changes measurably at menopause. Before the final period, oestrogen keeps LDL ('bad') cholesterol relatively low, HDL ('good') cholesterol higher, and blood vessels flexible. Within a year or two of menopause, LDL commonly rises by 10–15%, small dense LDL particles (the most atherogenic subtype) increase, HDL sometimes falls, and lipoprotein(a) — a genetically-driven, independently atherogenic particle — becomes fully expressed. Combined with rising blood pressure and central fat, this is why cardiovascular disease overtakes breast cancer as the leading cause of death in postmenopausal UK women. The reassuring counterpart is that cholesterol responds well to consistent midlife habits, and — where needed — to safe, effective medication.

The numbers worth knowing at menopause

Total cholesterol: aim for under 5 mmol/L (under 4 if established cardiovascular disease).
LDL: under 3 mmol/L (under 2 if established CVD or very high risk).
HDL: over 1.2 mmol/L in women.
Non-HDL cholesterol (total minus HDL): under 4 mmol/L — increasingly the preferred marker.
Triglycerides fasted: under 1.7 mmol/L.
Lipoprotein(a): check once in a lifetime — genetically fixed, adds independent risk if raised.
ApoB (if available): a stronger predictor than LDL — under 90 mg/dL for most women, under 70 mg/dL if high CVD risk.

First-line dietary changes

Soluble fibre — oats (porridge, oatcakes), pulses (lentils, chickpeas, beans), apples, pears, barley, psyllium. 5–10 g soluble fibre a day lowers LDL by around 5%.
Swap saturated fats for monounsaturated — extra-virgin olive oil, avocado, nuts, seeds. Reduce butter, cream, fatty red meat and processed meat.
Two portions of oily fish a week (salmon, mackerel, sardines, anchovies) — omega-3 lowers triglycerides significantly.
Plant sterols and stanols (in Benecol, Flora ProActiv and similar) — 2 g/day lowers LDL by around 10% if used consistently.
Nuts: a small handful daily (30 g) is associated with 5% LDL reduction.
Reduce refined carbohydrates and sugar — they raise triglycerides and small dense LDL more than dietary fat.
Mediterranean-style eating remains the strongest overall pattern for lipid improvement in midlife women.

Bowl of porridge with berries, nuts and seeds alongside a heart-healthy meal — 5–10 g of soluble fibre daily — oats, pulses, apples, barley, psyllium — reliably lowers LDL cholesterol.

Lifestyle levers beyond diet

150 minutes of Zone 2 cardio weekly raises HDL by 3–5% and lowers triglycerides by 10–20%.
Strength training 2–3 times a week improves the lipid profile independently, and supports healthy body composition.
Weight loss where BMI is raised: every 4–5 kg lost lowers LDL by around 8%.
Alcohol reduction — over 14 units/week raises triglycerides significantly.
Aim for a waist circumference under 80 cm — visceral fat is the strongest driver of atherogenic dyslipidaemia in midlife.
Stop smoking — smoking lowers HDL and damages the endothelium directly.
Sleep matters — persistent sleep of under 6 hours raises LDL and worsens insulin resistance.

When statins and other medications are considered

QRISK3 score of 10%+ (10-year cardiovascular risk) — usually prompts a statin conversation under NICE.
Established cardiovascular disease, type 2 diabetes, chronic kidney disease — usually a statin regardless of QRISK3.
Familial hypercholesterolaemia (very high LDL, family history of early heart disease) — always treated, referred to lipid clinic.
Very high triglycerides (over 10 mmol/L) — risk of pancreatitis; needs urgent treatment.
First-line statin in the UK: atorvastatin 20 mg (primary prevention) or 80 mg (secondary prevention). Simvastatin is largely superseded.
Ezetimibe, bempedoic acid, PCSK9 inhibitors (evolocumab, alirocumab) and inclisiran — added when statins alone aren't enough, or not tolerated.

Illustration of arteries showing atherosclerosis risk — After menopause, cardiovascular disease overtakes breast cancer as the leading cause of death — cholesterol is one of the most modifiable drivers.

Statin myths worth dispelling

'Statins ruin your muscles' — true muscle-related side effects affect around 5% of users; most muscle aches are age, deconditioning or vitamin D deficiency, and rechallenge is often successful.
'Statins cause diabetes' — a small absolute increase in diabetes incidence exists, but far outweighed by cardiovascular benefit in eligible women.
'Statins damage the liver' — clinically significant liver injury is rare; routine repeat LFTs beyond 3 months are usually unnecessary.
'I can lower cholesterol with diet alone' — often true for mild elevations; almost never true for familial hypercholesterolaemia or high 10-year risk.

HRT and cholesterol

Oral oestrogen (Elleste Solo, Premarin) lowers LDL by around 10–15% but raises triglycerides — usually a favourable trade-off unless triglycerides are already high.
Transdermal oestrogen (patch, gel, spray) is broadly neutral on lipids but has no clot risk — the preferred route where cholesterol is a concern.
HRT is not a substitute for statins in women with genuinely raised cardiovascular risk — the two can be used together.
Micronised progesterone (Utrogestan) is lipid-neutral; older synthetic progestogens (norethisterone, medroxyprogesterone) worsen the HDL profile.

Monitoring what matters

Full lipid profile every 5 years from 40 in low-risk women, more often if raised or on treatment.
Non-fasting is fine for total, HDL, LDL and non-HDL; triglycerides are more accurate fasted.
Recheck 3 months after starting a statin, then annually.
Lp(a) once in a lifetime — if raised, treat other risk factors more aggressively.
Combine with QRISK3, blood pressure and HbA1c at every menopause review — this is one conversation, not four.

Key takeaway

Cholesterol responds well to consistent midlife habits — Mediterranean-style eating, walking, strength training, alcohol moderation — and to safe, well-evidenced medication when needed. HRT can be part of the picture; it is not a substitute for treating cardiovascular risk properly.

How Dr Awal approaches this in clinic

Every consultation starts with your full story — symptoms, cycle, medical history, family history and what you've already tried. From there we look at whether hormonal treatment, non-hormonal options, lifestyle changes or a combination will give you the best result, and we tailor the plan to your age, risk factors and preferences.

A detailed 60 minute first appointment — no rushed 10-minute slots.
Evidence-based recommendations aligned with NICE NG23 and BMS guidance.
Body-identical HRT considered first-line where appropriate.
Shared-care letters sent to your NHS GP so treatment can continue affordably.
Follow-up at 3 months to fine-tune your regimen and address side effects.
Ongoing annual reviews so your plan evolves with you.

Common questions we hear about this

Do I need to be at a certain age to be seen?

No. We see women in early perimenopause (often late 30s and 40s), through post-menopause and beyond. Age alone doesn't decide whether treatment is right — symptoms, health history and goals do.

Will my GP continue the prescription?

In most cases yes. After your consultation we send a detailed shared-care letter with the diagnosis, treatment plan and rationale so your NHS GP can prescribe on the NHS. Not every practice accepts shared care — we'll discuss this in your appointment.

What if I've tried HRT before and it didn't suit me?

Very common — often the type, dose or route wasn't right rather than HRT itself. We review what you've tried, why it didn't work, and adjust accordingly. Many women who thought HRT wasn't for them do well on a different preparation.

How long will I need to stay on treatment?

There is no set upper time limit for HRT. Current BMS and NICE guidance supports continuing HRT for as long as the benefits outweigh the risks for you personally. We review this together every year so you stay in control of the decision.

Where do you see patients?

All consultations at Pause and Co Healthcare are conducted securely via video, allowing us to support patients anywhere in the UK. Prescriptions and shared care arrangements are managed in the same way, regardless of your location.

About the author

Dr Nadira Awal is a British Menopause Society Advanced Menopause Specialist with 15+ years' NHS and private experience. She holds the BMS Advanced Certificate in Menopause Care, sits on the BMS Programme Planning Group, and advises the UK Government Menopause Strategy Group. Read her full profile.

Sources & further reading

General information only — not a substitute for personalised medical advice. Always speak to your GP or a menopause specialist about your own situation.

Talk it through